Neuropathic Itch Caused by Pseudorabies Virus: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Peter Tang and Version 1 by Kathlyn Laval.

Pseudorabies virus (PRV) is an alphaherpesvirus related to varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV1). PRV is the causative agent of Aujeskzy’s disease in swine. PRV infects mucosal epithelium and the peripheral nervous system (PNS) of its host where it can establish a quiescent, latent infection. While the natural host of PRV is the swine, a broad spectrum of mammals, including rodents, cats, dogs, and cattle can be infected. Since the nineteenth century, PRV infection is known to cause a severe acute neuropathy, the so called “mad itch” in non-natural hosts, but surprisingly not in swine. In the past, most scientific efforts have been directed to eradicating PRV from pig farms by the use of effective marker vaccines, but little attention has been given to the processes leading to the mad itch. The main objective of this review is to provide state-of-the-art information on the mechanisms governing PRV-induced neuropathic itch. Current knowledge on the neurobiology and possible explanations for the unstoppable itch experienced by PRV-infected animals is also reviewed. We summarize recent findings concerning PRV-induced neuroinflammatory responses in mice and address the relevance of this animal model to study other alphaherpesvirus-induced neuropathies, such as those observed for VZV infection. 

  • Pseudorabies virus
  • neuropathic itch
  • immunopathogenesis
  • neuropathogenesis
  • swine
  • non-natural hosts
  • neuroinflammation

1. History of Aujeszky’s Disease

In 1813, a disease in cattle characterized by intense itching was first described in the USA. A similar disease appeared in Switzerland in 1849 and was mistaken for rabies because of the similar symptoms observed in cattle and dogs. In 1902, Aladár Aujeszky, a Hungarian veterinarian, first demonstrated the infectious nature of the agent and was able to distinguish the disease from rabies after experimental inoculation of rabbits with tissue suspensions from a diseased ox, a dog, and a cat. The infected rabbits showed excitation and nasal pruritus followed by convulsions and died within 60 h post-inoculation (hpi) [1]. Thus, the disease became known as “Aujeszky’s disease” (AD). In 1910, Schmiedhoffer confirmed that the disease was caused by a virus by performing filtration experiments [2]. From 1902 to 1930, only single outbreaks of AD were reported mainly in cattle and dogs in Hungary, Romania, France, Russia, and Brazil and the USA. At that time, the name “pseudorabies” was given to the disease in Europe because of its similarity to clinical rabies, while the term “mad itch” was mainly used in the USA. In 1931, Shope finally reported that mad itch and pseudorabies were caused by the same virus [3]. Three years later, he demonstrated that the agent of “mad itch” in cattle was also present in swine [4]. He also noted that the disease spread in swine herd and that, if cattle were pastured in the same lot, transmission from swine to cattle took place through abrasion of cattle skin. Surprisingly, the disease was not transmitted from cow to cow. In 1931, the Netherlands was the first country where the virus was reported to be enzootic in pigs. In the following years, sporadic outbreaks of PRV in pigs occurred worldwide and pigs were identified as a reservoir for the virus. In 1934, Sabin and Wright reported that AD virus (ADV)/pseudorabies virus (PRV) was serologically related to herpes simplex virus (HSV), resulting in the classification of the virus into the herpesvirus group [5][6][7].

2. Pseudorabies Virus (PRV)

PRV belongs to the family of the Herpesviridae, subfamily Alphaherpesvirinae, genus Varicellovirus. The virus is closely related to herpes simplex virus type 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV), causing cold sores, genital lesions, and chicken pox, respectively [8]. The virion is 150–180 nm in diameter and comprises four main structural components: Genome, capsid, tegument, and envelope. The viral genome consists of a linear double stranded DNA of approximately 150 kbp. The complete genome contains at least 70 open reading frames. The genome consists of a long unique region (UL) flanked by a short inverted repeat (TRL/IRL) linked to a short unique region (Us) flanked by an inverted repeat (TRS/IRS) [9]. The genome is enclosed in an icosahedral capsid, consisting of 162 capsomers. The genome and capsid together form the nucleocapsid that is surrounded by the tegument, a proteinaceous matrix that lines the space between the nucleocapsid and the envelope. Tegument proteins play an important role during virus entry, assembly, and egress [10]. The envelope consists of a bilayer of phospholipids derived from the trans-Golgi network of the host cell and contains different embedded glycoproteins. For PRV, 11 glycoproteins have been characterized (gB, gC, gD, gE, gG, gH, gI, gK, gL, gM, and gN) and named according to the nomenclature established for the related proteins of HSV-1. All glycoproteins are constituents of the virion, except gG, which is secreted into the medium by infected cells. The envelope proteins play important roles in virion binding and entry, envelopment, egress, cell-to-cell spread, induction of protective immunity, and immune evasion [11]. 

3.  The pathogenesis of PRV-induced neuropathic itch

 
3.1. Clinical classification of itch
Itch, also known as a pruritus, was defined in 1660 by a German physician Samuel Hafenreffler as an “unpleasant sensation that elicits the desire or reflex to scratch”. Pruritus can be acute or chronic [12]. Acute itch can be triggered by insect bites and relieved by scratching. Scratching, in turn, generates a mild pain that inhibits the itch sensation. In contrast, chronic itch can last for a longer period of time (>6 weeks duration) and scratching usually does not relieve the itch [13].
A clinical classification of chronic itch has been proposed by the International Forum for the Study of Itch and comprised 4 categories: the pruriceptive itch, the neurogenic itch, the neuropathic itch and the psychogenic itch (IFSI; http://www.itchforum.net). The first category is the pruriceptive itch that is caused by inflammatory skin disorders, such as atopic dermatitis, psoriasis, drug reactions, mites, and uticaria [14]. Pruriceptive itch originates following activation of primary afferent nerve terminals located in the skin. The main pruritogens, or itch-producing stimuli are histamine, interleukins, prostanglandins, and proteases. The second category is the neurogenic itch that results from CNS activation without necessary activation of sensory nerve fibers and is usually accompanied by visceral diseases such as chronic liver disease and chronic renal failure [15]. The third category is the neuropathic itch, a chronic condition that arises from viral-induced disease and/or traumatic nerve injury of the peripheral nervous system (PNS) or central nervous system (CNS), such as peripheral neuropathies (e.g., post-herpetic itch), multiple sclerosis and nerve compression or irritation (e.g., notalgia paresthethica, and brachoradial pruritus [16]. The main mediators of the neuropathic itch are neuropeptides, proteases and inflammatory mediators such as cytokines. Finally, the fourth category is the psychogenic itch related to psychological or psychiatric disorders, such as itch associated with delusions of parasitosis, stress and depression [17].
3.2. The neuropathic itch
Neuropathic itch (NI) is defined as perception of itch in the absence of pruritogenic stimuli [18]. NI can originate at any point along the sensory afferent pathway as a result of damage of the PNS and less frequently of the CNS. These PNS lesions occurs in sensory itch neurons including slow conducting myelinated (Aδ) and unmyelinated (C) nerve fibers [19]. In contrast, lesions that affect motor neurons are not associated with NI. NI are often characterized depending on the location of the nerve damage. For instance, brachioradial pruritus and notalgia paresthetica are focal NI, caused by damage of small fibers within cervical spinal nerves and damage to the cutaneous branches of the posterior divisions of the spinal nerves, respectively [20]. The most common focal NI arising from sensory ganglia lesions occurs during VZV reactivation within sensory ganglia, initially presenting as the zosteriform lesion known as shingles. In contrast, polyneuropathies arise from generalized peripheral nerve damage [21]. Finally, NI syndromes can also arise from lesions within the spinal cord (e.g., multiple sclerosis) and in the brain (stroke) [22]. In the brain, any types of lesions that damage itch circuitry can cause NI.
The mechanisms underlying the neuropathic itch are still poorly understood and data are scarce. The main consensus is that peripheral nerve injury activates PNS sensory itch neurons to fire excessively and thus, stimulate excitative interneurons in the dorsal horn of the spinal cord to release gastrin-releasing peptide (GRP). Then, the release of this neuropeptide further stimulates spinothalamic tract (STT) neurons that send itch signals to the thalamus [23][24]. Finally, these signals are relayed and processed in the somatosensory cortex. The central inhibition of itch pathway neurons in the brain that should be in turn activated, is likely dampened or disabled, resulting in an unstoppable itch sensation [25].
3.3. The neuronal mechanisms of PRV-induced neuropathic itch

PRV is a highly contagious pathogen that causes respiratory disease, neurological disorders and abortion in swine. Transmission occurs primarily through direct contact with oral and nasal secretions. Other animal species (non-natural hosts) are commonly infected through direct contact with pigs or through the consumption of raw offal from infected pigs. While PRV-infected swine do not itch and can survive the infection, non-natural hosts infected with the virus develop a severe pruritus and usually die within 2 days. In these animals, PRV enters nerve endings of the PNS that innervate the nasal mucosa of the upper respiratory tract and initiates a productive infection in PNS neurons. After replication in the PNS, progeny virions may spread in the retrograde direction from the PNS to the CNS if the animals survive long enough (Figure 1) [26]. 

Figure 1. Schematic representation of the pathogenesis of PRV in a non-natural host, the dog. (1) PRV first replicates in the epithelium of the upper respiratory tract; (a) PRV infection; (b) Viral spread within the respiratory epithelium and viral shedding; (c) PRV enters nerve endings of the PNS, including those coming from the trigeminal ganglia (TG) and spreads in the retrograde direction to the ganglia. (2) PRV initiates a productive infection in TG neurons; (a) PRV replicates in cell bodies of TG neurons; (b) New progeny virions can further spread in the anterograde direction and infect the CNS (brainstem). Purple = respiratory tract; yellow = TG.

Based on studies of the pathogenesis of PRV in non-natural hosts, it was therefore proposed that the continuous PRV replication in PNS ganglia causes neuronal lesions that are responsible for the initiation of the pruritus in these animals. Several animal models have been used to further dissect the mechanisms by which PRV replication in PNS neurons cause pruritus. A study from Dempsher and colleagues first demonstrated that PRV induces spontaneous, intermittent discharge of nerve impulses over the preganglionic and postganglionic nerves of superior cervical ganglia following ocular inoculation. The spontaneous discharges were only found in PRV-infected sympathetic ganglia of rats showing pruritus [27]. Similar results were observed after intraocular and intradermal PRV inoculations in rats [28]. Interestingly, inoculation with a PRV pruritus-producing strain (L strain) induced spontaneous hyperexcitability of neurons. In contrast, the non-pruritus producing strain (G strain), known to cause meningoencephalitis, exhibited impaired sympathetic synaptic conduction in infected rats [29]. Voltage-gated sodium and calcium channels were found to be responsible for the initiation and propagation of action potential (AP) in the infected ganglia [28].
In addition, PRV infection induces electrical coupling and increases AP firing rates in cultured rat sympathetic neurons in vitro [30]. The formation of fusion pores between infected PNS neurons was found to be mediated by PRV gB. PRV gB protein is an important component of the viral membrane fusion complex (gB/gH/gL) and is crucial for viral entry into neurons [31]. The production of fusion pores facilitates the flow of ions between PNS neurons and causes direct electrical coupling. Moreover, it was demonstrated that infection of PNS neurons of the submandibular ganglia with a virulent PRV pruritus-producing strain (PRV-Becker) induces synchronous and cyclical activity in neuronal cell bodies [32]. Also, it was found that newly made virus particles in infected neurons were transported in axons back to the glands where the infection started. Thus, the authors introduced the concept of “round-trip” reseeding and amplification of the infection in the ganglia. The ability to reseed the gland increases the infection of the innervating ganglia and the involvement of more axons in electrical firing, therefore directly contributing to the pruritus. In contrast, mice infected with an attenuated, live vaccine and non-pruritus producing strain (PRV-Bartha) did not show signs of synchronous and cyclical activity in infected ganglia. This difference was attributed to the fact that PRV-Bartha lacks the US9 protein required for sorting virion proteins into axons [33]. Recent results are in agreement with the PRV round-trip concept. For instance, a large amount of infectious virus was detected in the mouse footpad at moribund state after footpad inoculation. Likely, it resulted from virus particles that originally infected the DRG, replicated and went back to the footpad rather than from local viral replication in the footpad. Indeed, the inoculated footpad, which exhibited epidermal necrosis accompanied by immune cell infiltrates, did not have time to regenerate and support efficient viral replication [34].
Finally, a comparative study of the neuroinvasive mechanisms between virulent PRV-Becker and attenuated PRV-Bartha was performed using the mouse flank inoculation model. In contrast to PRV-Becker infection, mice infected with PRV-Bartha did not develop pruritus and lived twice as long. However, they did show severe CNS symptoms due to widespread PRV-Bartha infection in the brain and eventually died of viral encephalitis. Using several PRV mutants, the authors demonstrated that the pruritus stimulus was mainly mediated by US9, gE and gI proteins [35] . These 3 gene products, which are deleted in the PRV-Bartha strain, are required for virulence and efficient anterograde spread of PRV within the nervous system [33][36][37].
3.4.The immune mechanisms of PRV-induced neuropathic itch
The immune system plays a crucial role in the development of neuropathic itch. In the case of a pruriceptive itch, skin inflammation results in the recruitment and activation of immune cells to the skin epithelium. Activated immune cells release pro-inflammatory mediators, such as interleukin (IL)-31 and IL-33 that sensitize pruriceptors, leading to peripheral sensitization and activation of itch signaling pathways [38]. In the case of a neuropathic itch, peripheral nerve injury can cause inflammation of the nervous system, so called neuroinflammation. The PNS and CNS neurons as well as resident satellite glia, microglia, and astrocytes can also produce inflammatory mediators, including pro-inflammatory cytokines and chemokines, neuropeptides and reactive oxygen species. The release of neuropeptides such as substance P and calcitonin gene-related peptide (CGRP) by activated primary sensory neurons has been shown to have paracrine effects on immune cells and can increase the inflammation and subsequently amplify the itch sensation [39][40]. The same localized immune activation can be mimicked after viral infection of PNS neurons. For instance, reactivation of VZV from sensory ganglia causes a self-limited dermatomal rash with pain and itching, which is accompanied by inflammation of the skin [41].
Several cases of PRV-induced neuropathic itch reported mild purulent ganglioneuritis and encephalomyelitis in non-natural hosts, thus suggesting that PRV infection of sensory ganglia is accompanied by a specific inflammatory response. Indeed, perivascular cuffing of lymphocytes, monocytes and macrophages as well as a neutrophilic cell infiltration were detected in PRV-infected ganglia. So far, only a few studies investigated the role of the inflammatory response in the initiation and development of PRV-induced neuropathic itch. By the use of the mouse flank inoculation model, PRV-Becker infected mice, that were anesthetized at the time the pruritus started, did not develop skin lesions. Still, these mice died as the same time as the non-anesthetized ones. These results suggested that self-mutilation and scratching alone were not the cause of death. The authors then mentioned that a peripheral host immune response to PRV infection of the PNS could be an important factor in the death of the infected animals [35]. Using the footpad inoculation model, it was later shown that virulent PRV-Becker, but not attenuated PRV-Bartha, infection induces a specific and lethal systemic inflammatory response in mice. High levels of IL-6 and granulocyte colony-stimulating factor (G-CSF) were measured in both tissues and plasma of infected animals, including the footpad and dorsal root ganglia (DRG) at moribund stage [34]. Furthermore, a strong correlation was found between the level of infectious virus detected in the DRG and footpad and the production of pro-inflammatory cytokines. Indeed, PRV-Becker replicated to a higher level in both tissues than PRV-Bartha. The fact that PRV-Becker was able to reseed new progeny virions back from the DRG neurons to the footpad might also have contributed to the amplification of the inflammatory response. Figure 2 shows a model of PRV-induced neuropathic itch in non-natural hosts.
Figure 2. Model of PRV-induced neuropathic itch in non-natural hosts. (1) (a) Efficient viral replication and spread of PRV in the respiratory epithelium; (b) PRV particles activate axons terminals of sensory PNS neurons; (c) Activated sensory PNS neurons trigger inflammatory signaling pathways and produce pro-inflammatory cytokines that are released in PNS neurons and locally at axon terminals. (2) (d) Efficient PRV replication in cell bodies of PNS neurons and release of new progeny virions; (e) Spontaneous hyperexcitability of neurons and increase of action potential firing as well as (f) reseeding of new progeny virions back to the epithelium increases electrical coupling of axons and contributes to the pruritus; (b) Amplification of the inflammatory response in PNS neurons; (h) The production of pro-inflammatory cytokines in PNS neurons attract neutrophils and other immune cells to the site of infection and propagate the neuroinflammation. (3) (i) Release of neuropeptides from activated PNS neurons stimulate excitative interneurons in the dorsal horn of the spinal cord; (j) The excitation spreads to spinothalamic tract neurons, which in turn send neuroinflammatory itch signals to the brain; (k) These signals are relayed and processed in the somatosensory cortex. (4) The central itch inhibition pathways are likely dampened or disabled, resulting in an unstoppable pruritus.
Both IL-6 and G-CSF are produced by immune cells (neutrophils, T lymphocytes and macrophages) and neurons. While IL-6 has pleiotropic effects on immune response, inflammation, hematopoiesis and neurogenesis, G-CSF is mainly a key regulator of neutrophil function, mainly influencing the migration of neutrophils across the vascular endothelium [42][43]. Taken together, the high concentrations of G-CSF and IL-6 detected in the infected footpad and DRG of experimentally infected mice are likely to correlate with histological findings from naturally infected animals where a massive neutrophilic infiltration is observed in the PRV-infected ganglia. Furthermore, neutrophils can induce neurotoxicity on DRG neurons and are considered responsible for hypersensitivity and neuropathic pain observed after peripheral nerve injury [44]. Therefore, their accumulation around the infected ganglia may further amplify the neuroinflammation.
The early events of the neuroinflammatory response of PRV infection in mice were recently characterized. Using the mouse footpad inoculation model, it was demonstrated that PRV-Becker infection primes DRG neurons to a state of inflammation very early post-infection [45][46]. More specifically, the authors found that the peak of IL-6 and G-CSF production detected in the DRGs and footpad of infected mice at 7 hpi could not be attributed to the infiltration of neutrophils in these tissues that occurred at 82 hpi. An efficient replication of PRV-Becker and subsequent spread in the footpad were necessary to activate DRG neurons to produce G-CSF at a very early time pi. Moreover, PRV replication was limited in the footpad of Toll-like receptor 2 (TLR2) knockout (KO) mice with no viral replication detected in DRG neurons. TLRs are expressed in nociceptive neurons and play a crucial role in neuroinflammation [47]. In particular, TLR2 is responsible for the activation of spinal cord glial cell after nerve injury and subsequent pain hypersensitivity [48]. Thus, the results suggested that TLR2 might be a potential receptor for PRV on DRG neurons, thus facilitating viral spread and the initiation of the neuroinflammatory response in mice. PRV gB expressed on new progeny virions or infected epidermal cells was proposed as a potential candidate to interact with TLR2 expressed on axon terminals of DRG neurons that are innervating the footpad.

4. PRV infection in mice: a new animal model for VZV-induced peripheral neuropathies 

A better understanding of PRV-induced neuroinflammatory responses in mice may provide new insights in the initiation and development of virus-induced neuroinflammation during other herpesvirus infections. For instance, this animal model could be useful to dissect the mechanisms of neuropathic itch in patients with post-herpetic lesions (e.g. herpes zoster (HZ); shingles). Indeed, the neuropathogenesis and immunopathogenesis of VZV and PRV infections are remarkably similar. Reactivation of VZV causes a self-limited dermatomal rash with pain and itching, which is accompanied by inflammation of the skin. The HZ lesions can be reduced by treatment with antivirals [49]. However, postherpetic neuralgia (PHN) and postherpetic itch (PHI) are two common complications of HZ that can occur in some cases in up to 50% of patients with shingles [50].

PHN consists of a burning and stabbing pain while PHI is characterized by a relentless itch in the same area of the HZ rash, resulting in serious injuries due to scratching. Both PHN and PHI can last for months or years after resolution of the HZ rash, thus severely impacting the life quality of infected people. Antiviral therapy for acute HZ does not eliminate the risk of PHN, and no beneficial effect of any antiviral drug on established PHN has been shown. It was suggested that PHN is caused by VZV-induced inflammation and axonal damage, which gives rise to hyperexcitability, marked by spontaneous firing of PNS neurons. These neurons may have a lower excitation threshold to pain, thus causing neuropathic pain [51]. In contrast, the underlying mechanism(s) of PHI is largely unknown. Despite some similarities between itch and pain pathways, treatments against pain are not efficient in relieving itch. Current treatments against neuropathic itch are very limited and lack specificity, and for many patients with PHI no alleviation can be provided [52].

The narrow host range and lack of clinical disease have limited the use of animal models to investigate the pathogenesis of VZV infection [53]. So far, investigation of PHI has been limited by the lack of a relevant in vivo neuropathic itch animal model. Interestingly, VZV and PRV infections present multiple similarities in genome sequence, clinical signs, pathogenesis and immunity. At the level of innate immunity, the exact same concentration of IL-6 (∼30,000 pg/ml) has been demonstrated in both VZV-infected human explants and PRV-infected mouse footpad by ELISA [54][45]. Since VZV does not productively replicate in rodents, PRV-induced neuropathic itch in mice may represent a promising model to further understand the pathogenesis of PHI caused by VZV infection.

5. Conclusions

Since the first case of mad itch was described 207 years ago, the characteristic pruritus caused by PRV infection in non-natural hosts has been frequently reported throughout the years. Currently, relatively few studies have focused on this particular aspect of PRV pathogenesis. This paucity of information is mainly because PRV remained a major viral disease in swine, causing substantial economic losses to pig producers. Therefore, the efforts of the research community were primarily focused on developing effective vaccines aimed at eradication of the virus. Recently, researchers dissected the molecular and cellular mechanisms of PRV-induced neuropathic itch using several mouse models and emphasized the innate immune response as a central player. Good control of the inflammatory response during PRV infection of swine likely prevents the neuropathic pruritus experienced by infected non-natural hosts. Most importantly, PRV infection of mice has proven to be a suitable animal model to study PRV-induced neuropathic itch. This animal model may also provide useful insights into the pathogenesis of other herpesvirus infections, such as those following VZV infection. The model may lead to the development of innovative therapeutic strategies.[9]

References

  1. A. Aujeszky; Uber eine neue Infektion krankheit bei Haustieren. Zbl Bakt Abt Orig 1902, 32, 353-357.
  2. J. Schmiedhoffer; Beiträge zur Pathologieder infektiösen Bulbär paralyse (Aujeszky-schen Krankheit). Z Infekt Krankh Parasit Hyg Haustier 1910, 8, 383-405.
  3. R.E. Shope; An experimental study of ‘mad itch’ with especial reference to its relationship to pseudorabies. Journal of Experimental Medicine 1931, 54, 233-248.
  4. R.E. Shope; Pseudorabies is a contagious disease in swine. Science 1934, 80, 102-103.
  5. A.B. Sabin; The immunological identity of a virus isolated from a human case of ascending myelitis associated with visceral necrosis. Journal of Experimental Pathology 1934, 15, 248-268.
  6. A.B. Sabin; Acute ascending myelitis following monkey bite with isolation of a virus capable of reproducing disease. Journal of Experimental Medicine 1934, 59, 115.
  7. A.B. Sabin; Progression of different nasally installed viruses along different nervous pathways in the same host. Proceedings of the Society for Experimental Biology and Medicine 1938, 38, 270-275.
  8. I. Steiner; P.G.E. Kennedy; A.R. Pachner; The neurotropic herpes viruses: herpes simplex and varicella-zoster. The Lancet Neurology 2007, 6, 1015-1028.
  9. Barbara G. Klupp; Christoph J. Hengartner; Thomas C. Mettenleiter; Lynn W. Enquist; Complete, Annotated Sequence of the Pseudorabies Virus Genome. Journal of Virology 2004, 78, 424-440, 10.1128/jvi.78.1.424-440.2004.
  10. T.C. Mettenleiter; Herpesvirus assembly and egress. Journal of Virology 2002, 76, 1537-1547.
  11. Lisa E. Pomeranz; Ashley E. Reynolds; Christoph J. Hengartner; Molecular Biology of Pseudorabies Virus: Impact on Neurovirology and Veterinary Medicine. Microbiology and Molecular Biology Reviews 2005, 69, 462-500, 10.1128/mmbr.69.3.462-500.2005.
  12. Akihiko Ikoma; Martin Steinhoff; Sonja Ständer; Gil Yosipovitch; Martin Schmelz; The neurobiology of itch. Nature Reviews Neuroscience 2006, 7, 535-547, 10.1038/nrn1950.
  13. Dustin Green; Xinzhong Dong; The cell biology of acute itch. Journal of Cell Biology 2016, 213, 155-161, 10.1083/jcb.201603042.
  14. Gil Yosipovitch; Alan B Fleischer; Itch Associated with Skin Disease. American Journal of Clinical Dermatology 2003, 4, 617-622, 10.2165/00128071-200304090-00004.
  15. A. Galatian; G. Stearns; R. Grau; Pruritus in connective tissue and other common systemic disease states. Cutis 2009, 84, 207-214.
  16. Andreas Binder; Jana Koroschetz; Ralf Baron; Disease mechanisms in neuropathic itch. Nature Clinical Practice Cardiovascular Medicine 2008, 4, 329-337, 10.1038/ncpneuro0806.
  17. Gil Yosipovitch; Lena S Samuel; Neuropathic and psychogenic itch. Dermatologic Therapy 2008, 21, 32-41, 10.1111/j.1529-8019.2008.00167.x.
  18. Anne Louise Oaklander; Neuropathic Itch. Seminars in Cutaneous Medicine and Surgery 2011, 30, 87-92, 10.1016/j.sder.2011.04.006.
  19. M. Ringkamp; R. Meyer. Frontiers in Neuroscience Pruriceptors; E. Carstens and T. Akiyama, Eds.; in Itch: Mechanisms and Treatment: CRC Press/Taylor & Francis(c), LLC.: Boca Raton (FL), 2014; pp. N/A.
  20. B.A. Robbins; G.J. Scmieder. Brachioradial pruritus; StatPearls, Eds.; StatPearls: StatPearls Publishing StatPearls Publishing LLC.: Treasure Island (FL)., 2020; pp. N/A.
  21. Asit Mittal; Ankita Srivastava; Manisha Balai; Ashok Kumar Khare; A study of postherpetic pruritus. Indian Dermatology Online Journal 2016, 7, 343-344, 10.4103/2229-5178.185479.
  22. M.C. Koeppel; C. Bramont; M. Ceccaldi; M. Habib; J. Sayag; Paroxysmal pruritus and multiple sclerosis. British Journal of Dermatology 1993, 129, 597-598, 10.1111/j.1365-2133.1993.tb00492.x.
  23. Martin Steinhoff; Martin Schmelz; Imre Lőrinc Szabó; Anne Louise Oaklander; Clinical presentation, management, and pathophysiology of neuropathic itch. The Lancet Neurology 2018, 17, 709-720, 10.1016/s1474-4422(18)30217-5.
  24. Steve Davidson; Xijing Zhang; Sergey G Khasabov; Donald A Simone; Glenn J Giesler Jr; Relief of itch by scratching: state-dependent inhibition of primate spinothalamic tract neurons. Nature Neuroscience 2009, 12, 544-546, 10.1038/nn.2292.
  25. Gil Yosipovitch; Yozo Ishiuji; Tejesh S. Patel; Maria Isabel Hicks; Yoshitetsu Oshiro; Robert A. Kraft; Erica Winnicki; Robert C. Coghill; The Brain Processing of Scratching. Journal of Investigative Dermatology 2008, 128, 1806-1811, 10.1038/jid.2008.3.
  26. Kathlyn Laval; Lynn W. Enquist; The Neuropathic Itch Caused by Pseudorabies Virus. Pathogens 2020, 9, 254, 10.3390/pathogens9040254.
  27. John Dempsher; Martin G. Larrabee; Frederik B. Bang; David Bodian; Physiological Changes in Sympathetic Ganglia Infected With Pseudorabies Virus. American Journal of Physiology-Legacy Content 1955, 182, 203-216, 10.1152/ajplegacy.1955.182.1.203.
  28. G.S. Liao; M. Maillard; M. Kiraly; Ion channels involved in the presynaptic hyperexcitability induced by herpes virus suis in rat superior cervical ganglion. Neuroscience 1991, 41, 797-807, 10.1016/0306-4522(91)90370-4.
  29. T. Tokumaru; Pseudorabies virus - induced neural hyperreactivity following occular and skin infections in the rat. Research communications in chemical pathology and pharmacology 1975, 10, 533-542.
  30. Kelly M. McCarthy; David W. Tank; Lynn W. Enquist; Pseudorabies Virus Infection Alters Neuronal Activity and Connectivity In Vitro. PLOS Pathogens 2009, 5, e1000640, 10.1371/journal.ppat.1000640.
  31. Herman Favoreel; Geert Van Minnebruggen; Hans J. Nauwynck; Lynn W. Enquist; Maurice B. Pensaert; A Tyrosine-Based Motif in the Cytoplasmic Tail of Pseudorabies Virus Glycoprotein B Is Important for both Antibody-Induced Internalization of Viral Glycoproteins and Efficient Cell-to-Cell Spread. Journal of Virology 2002, 76, 6845-6851, 10.1128/jvi.76.13.6845-6851.2002.
  32. Andrea E. Granstedt; Jens Bernhard Bosse; Stephan Thiberge; Lynn W. Enquist; In vivo imaging of alphaherpesvirus infection reveals synchronized activity dependent on axonal sorting of viral proteins. Proceedings of the National Academy of Sciences 2013, 110, E3516-E3525, 10.1073/pnas.1311062110.
  33. A. D. Brideau; J. P. Card; L. W. Enquist; Role of Pseudorabies Virus Us9, a Type II Membrane Protein, in Infection of Tissue Culture Cells and the Rat Nervous System. Journal of Virology 2000, 74, 834-845, 10.1128/jvi.74.2.834-845.2000.
  34. K. Laval; J. B. Vernejoul; J. Van Cleemput; O. O. Koyuncu; L. W. Enquist; Virulent Pseudorabies Virus Infection Induces a Specific and Lethal Systemic Inflammatory Response in Mice. Journal of Virology 2018, 92, e01614-18, 10.1128/jvi.01614-18.
  35. Elizabeth E. Brittle; Ashley E. Reynolds; L. W. Enquist; Two Modes of Pseudorabies Virus Neuroinvasion and Lethality in Mice. Journal of Virology 2004, 78, 12951-12963, 10.1128/jvi.78.23.12951-12963.2004.
  36. Paul J. Husak; Timothy Kuo; L. W. Enquist; Pseudorabies Virus Membrane Proteins gI and gE Facilitate Anterograde Spread of Infection in Projection- Specific Neurons in the Rat. Journal of Virology 2000, 74, 10975-10983, 10.1128/jvi.74.23.10975-10983.2000.
  37. M. Yang; J. P. Card; R. S. Tirabassi; R. R. Miselis; L. W. Enquist; Retrograde, Transneuronal Spread of Pseudorabies Virus in Defined Neuronal Circuitry of the Rat Brain Is Facilitated by gE Mutations That Reduce Virulence. Journal of Virology 1999, 73, 4350-4359, 10.1128/jvi.73.5.4350-4359.1999.
  38. Martin Schmelz; Itch Processing in the Skin.. Frontiers in Medicine 2019, 6, 167, 10.3389/fmed.2019.00167.
  39. Smriti Iyengar; Michael H. Ossipov; Kirk W. Johnson; The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine. Pain 2017, 158, 543-559, 10.1097/j.pain.0000000000000831.
  40. Xue Feng Wang; Tong Tong Ge; Jie Fan; Wei Yang; Bingjin Li; Ran Ji Cui; The role of substance P in epilepsy and seizure disorders. Oncotarget 2017, 8, 78225-78233, 10.18632/oncotarget.20606.
  41. Niklaus H. Mueller; Donald H. Gilden; Randall J. Cohrs; Ravi Mahalingam; Maria A. Nagel; Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis of Disease, and Latency. Neurologic Clinics 2008, 26, 675-697, 10.1016/j.ncl.2008.03.011.
  42. Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto; IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology 2014, 6, a016295-a016295, 10.1101/cshperspect.a016295.
  43. Kwee Yong; Granulocyte colony‐stimulating factor (G‐CSF) increases neutrophil migration across vascular endothelium independent of an effect on adhesion: comparison with granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). British Journal of Haematology 1996, 94, 40-47, 10.1046/j.1365-2141.1996.d01-1752.x.
  44. S.K. Shaw; S.A. Owolabi; J. Bagley; N. Morin; E. Cheng; B.W. LeBlanc; M. Kim; P. Harty; S.G. Waxman; C.Y. Saab; et al. Activated polymorphonuclear cells promote injury and excitability of dorsal root ganglia neurons. Experimental Neurology 2008, 210, 286-294, 10.1016/j.expneurol.2007.11.024.
  45. Kathlyn Laval; Jolien Van Cleemput; Jonah B. Vernejoul; Lynn W. Enquist; Alphaherpesvirus infection of mice primes PNS neurons to an inflammatory state regulated by TLR2 and type I IFN signaling. PLOS Pathogens 2019, 15, e1008087, 10.1371/journal.ppat.1008087.
  46. Kathlyn Laval; Carola J. Maturana; Lynn W. Enquist; Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses. Journal of Visualized Experiments 2020, N/A, e61121, 10.3791/61121.
  47. Carmen D. Rietdijk; Richard J. A. Van Wezel; Johan Garssen; Aletta D. Kraneveld; Neuronal toll-like receptors and neuro-immunity in Parkinson's disease, Alzheimer's disease and stroke. Neuroimmunology and Neuroinflammation 2016, 3, 27, 10.20517/2347-8659.2015.28.
  48. Donghoon Kim; Myung Ah Kim; Ik-Hyun Cho; Mi Sun Kim; Soojin Lee; Eun-Kyeong Jo; Se-Young Choi; Kyungpyo Park; Joong Soo Kim; Shizuo Akira; et al.Heung Sik NaSeog Bae OhSung Joong Lee A Critical Role of Toll-like Receptor 2 in Nerve Injury-induced Spinal Cord Glial Cell Activation and Pain Hypersensitivity. Journal of Biological Chemistry 2007, 282, 14975-14983, 10.1074/jbc.m607277200.
  49. Jr. John W. Gnann; Varicella‐Zoster Virus: Atypical Presentations and Unusual Complications. The Journal of Infectious Diseases 2002, 186, S91-S98, 10.1086/342963.
  50. Rhonda G. Kost; Stephen E. Straus; Postherpetic Neuralgia — Pathogenesis, Treatment, and Prevention. New England Journal of Medicine 1996, 335, 32-42, 10.1056/nejm199607043350107.
  51. Gary J Bennett; C Peter N Watson; Herpes Zoster and Postherpetic Neuralgia: Past, Present and Future. Pain Research and Management 2009, 14, 275-282, 10.1155/2009/380384.
  52. Valentina Semionov; Pesach Shvartzman; Post Herpetic Itching—A Treatment Dilemma. The Clinical Journal of Pain 2008, 24, 366-368, 10.1097/ajp.0b013e3181633fb1.
  53. Kristen Haberthur; Ilhem Messaoudi; Animal Models of Varicella Zoster Virus Infection. Pathogens 2013, 2, 364-382, 10.3390/pathogens2020364.
  54. Keith W Jarosinski; John E Carpenter; Erin M Buckingham; Wallen Jackson; Kevin Knudtson; Jennifer F Moffat; Hirohito Kita; Charles Grose; Cellular Stress Response to Varicella-Zoster Virus Infection of Human Skin Includes Highly Elevated Interleukin-6 Expression. Open Forum Infectious Diseases 2018, 5, ofy118, 10.1093/ofid/ofy118.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback